Zepbound Dosage Chart 2026: Approved Schedule, KwikPen Strengths, and Titration Rules

The approved Zepbound (tirzepatide, weight-management brand) dosage schedule, reproduced for reference from the FDA-approved product label: the six KwikPen strengths, the label's four-week step structure, the missed-dose window, and how the product differs from Mounjaro and Wegovy. This page reproduces the approved label as reference information only. It is not an instruction to any reader, and prescribing decisions belong to a licensed clinician.

The Approved Zepbound Schedule (per the FDA-Approved Label)

Zepbound is the weight-management brand of tirzepatide. As a matter of label fact, the FDA-approved label lists six strengths — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg — and specifies a once-weekly dosing interval. The label's stated escalation structure is four weeks at each step, beginning at 2.5 mg for weeks 1-4, then 5 mg, then 7.5 mg, 10 mg, and 12.5 mg, with 15 mg listed as the approved maximum maintenance strength. The label describes 2.5 mg as a starting dose and states it is not intended as a maintenance dose. This section reproduces those label statements for reference; it does not direct any reader to take any amount. Search queries phrased as "zepbound how often to inject" and "zepbound dosage chart" map to this same published label structure, and a "tirzepatide weight loss dose" table returns the identical six strengths because Zepbound and Mounjaro share one molecule.

KwikPen Strengths and Delivery

The label lists Zepbound in the six KwikPen strengths matching the schedule (2.5 through 15 mg), each pen delivering four weekly doses. As reference notes, the label describes the kwikpen as a single-patient device with doses fixed per pen strength, and because every step is a four-week adaptation step the label notes that pens are not strength-interchangeable mid-schedule without a prescriber's direction. The "how many units is 7.5 mg" style queries that circulate in forums are unit-conversion questions; our conversion tool performs concentration and volume math on stated amounts as lab reference arithmetic, not dosing guidance. Pen pricing is reported as roughly uniform across strengths, so the cost variable is treatment duration, not dose level — our cost comparison tracks the programs.

Schedule Steps, Missed Doses, and Reported Side Effects

The four-week steps exist because dose-response in tirzepatide is strong in the published data: reported trial weight loss scaled from about 15% at 5 mg toward about 21% at 15 mg, and GI effects were reported to scale with dose in the escalation weeks. The approved label's missed-dose guidance, reproduced here as reference, states that a dose may be taken within 96 hours (4 days), and that the next scheduled weekly dose is otherwise resumed; after two missed doses the label directs contacting the prescriber. The label notes that GI symptoms in the escalation weeks are managed under prescriber guidance. Our research calculators reproduce the same schedule as reference data; the ladder is the published reference, and any change to a labelled schedule is a prescriber decision, not a reader action.

Zepbound in the 2026 Landscape

Zepbound (tirzepatide) is reported as the efficacy leader among approved GLP-1 options: ahead of Wegovy (semaglutide, about 15%) on trial weight loss, behind investigational retatrutide (up to 31% in TRIUMPH), and now sharing the market with the first oral option (orforglipron) at the convenience tier. The active lawsuits over claimed serious side effects are the 2026 storyline our news section tracks; the label's four-week steps are the reference the litigation underscores. For researchers comparing molecules, our semaglutide-vs-tirzepatide guide is the head-to-head reference, and the calculator set covers every approved and investigational schedule in the class.

📊 Dosage Calculator & Protocol Chart

Convert reported label amounts into concentration and volume figures for reference:

👉 Zepbound Dosage Calculator — Concentration and volume conversions for the amounts named in the approved label.

👉 Full Dosing Guide & Protocol Chart — The approved schedule, reported trial data, and study parameters in one reference place.

Important Disclaimer

This article is for educational and research purposes only. Zepbound is an FDA-approved product; this page reproduces its approved label schedule for reference, and nothing here is medical advice or a prescribing recommendation. Prescribing decisions belong to a licensed clinician. The information provided here is synthesized from published research, clinical trial data, and community discussions.

Keywords: zepbound dosage chart, zepbound how often to inject, zepound dosing, zepbound kwikpen, tirzepatide weight loss dose

Sources: Published research papers, clinical trial databases, community discussions, peptiq.io educational content